BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 10803455)

  • 1. Adaptive control methods for the dose individualisation of anticancer agents.
    Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
    Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.
    Rousseau A; Marquet P
    Fundam Clin Pharmacol; 2002 Aug; 16(4):253-62. PubMed ID: 12570013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical treatment guide for dose individualisation in cancer chemotherapy.
    Canal P; Chatelut E; Guichard S
    Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.
    Rousseau A; Sabot C; Delepine N; Delepine G; Debord J; Lachâtre G; Marquet P
    Clin Pharmacokinet; 2002; 41(13):1095-104. PubMed ID: 12403645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.
    Loh GW; Ting LS; Ensom MH
    Clin Pharmacokinet; 2007; 46(6):471-94. PubMed ID: 17518507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB; Robinson BA
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of cancer chemotherapy.
    Alnaim L
    J Oncol Pharm Pract; 2007 Dec; 13(4):207-21. PubMed ID: 18045780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A sequential Bayesian algorithm for dose individualisation of carboplatin.
    Duffull SB; Begg EJ; Robinson BA; Deely JJ
    Cancer Chemother Pharmacol; 1997; 39(4):317-26. PubMed ID: 9025772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes.
    Masson E; Zamboni WC
    Clin Pharmacokinet; 1997 Apr; 32(4):324-43. PubMed ID: 9113440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
    Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
    Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can pharmacokinetic and pharmacodynamic studies improve cancer chemotherapy?
    Newell DR
    Ann Oncol; 1994; 5 Suppl 4():9-14; discussion 15. PubMed ID: 8060901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring.
    Kobayashi K; Jodrell DI; Ratain MJ
    Cancer Surv; 1993; 17():51-78. PubMed ID: 8137353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity.
    Evans WE
    Blut; 1988 Jun; 56(6):241-8. PubMed ID: 3289632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation.
    van der Meer AF; Marcus MA; Touw DJ; Proost JH; Neef C
    Ther Drug Monit; 2011 Apr; 33(2):133-46. PubMed ID: 21383653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics and individual dose adjustment of carboplatin].
    Chatelut E; Canal P; Bugat R
    Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?
    Tod MM; Padoin C; Petitjean O
    Clin Pharmacokinet; 2001; 40(11):803-14. PubMed ID: 11735603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects].
    Marquet P
    Acta Clin Belg; 1999; 53 Suppl 1():2-12. PubMed ID: 10216973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring in cancer management.
    Galpin AJ; Evans WE
    Clin Chem; 1993 Nov; 39(11 Pt 2):2419-30. PubMed ID: 8222253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback.
    Monjanel-Mouterde S; Ciccolini J; Bagarry D; Zonta-David M; Duffaud F; Favre R; Durand A
    J Clin Pharm Ther; 2003 Apr; 28(2):109-16. PubMed ID: 12713607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.
    Hénin E; Tod M; Trillet-Lenoir V; Rioufol C; Tranchand B; Girard P
    Clin Pharmacokinet; 2009; 48(6):359-69. PubMed ID: 19650675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.